

SUPPLEMENTARY TABLE 2. Odds Ratios for Pertussis Disease Associated with Pertussis Vaccination and Estimated Vaccine Effectiveness Without Matching by Facility — Alaska, May–November 2024

Characteristic	DTaP vaccination status		
	Fully vaccinated*	Partially Vaccinated [†]	Unvaccinated [§]
Study group[¶]			
Case-patients (n = 106), no. (%)	24 (22.6)	12 (11.3)	70 (66.0)
Control patients (n = 322), no. (%)	248 (77.0)	38 (11.8)	36 (11.2)
OR for pertussis disease relative to unvaccinated children (95% CI)			
Unadjusted	0.0 (0.0–0.1)	0.1 (0.1–0.3)	1 [Reference]
Adjusted**	0.1 (0.0–0.1)	0.1 (0.1–0.3)	1 [Reference]
OR for pertussis disease relative to fully vaccinated children (95% CI)^{††}			
Unadjusted	1 [Reference]	2.7 (1.5–4.7)	22.7 (12.3–42.2)
Adjusted**	1 [Reference]	2.8 (1.5–5.1)	19.8 (9.6–40.9)
Pertussis VE, % (95% CI)			
Unadjusted	95.1 (90.3–97.5)	87.4 (71.5–94.4)	1 [Reference]
Adjusted**	94.7 (89.1–97.4)	85.4 (69.8–92.9)	1 [Reference]

Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; OR = odds ratio; VE = vaccine effectiveness.

* Documented receipt of ≥3 DTaP doses

[†] Documented receipt of 1 or 2 DTaP doses

[§] No documented receipt of any DTaP dose

[¶] Participants matched by birth year and facility

** Adjusted for patient race, sex, and calendar month